

**A broadly neutralizing monoclonal antibody targeting  
HCV prevents viral infection *in vitro* and  
in human liver chimeric mice**

**Ahmed A. Mesalam**

Center for Vaccinology  
Ghent University



# Introduction

- **Hepatitis C virus:** positive stranded RNA virus  
enveloped particle: E1 and E2  
7 genotypes  
DAA therapies: improved SVR
- **HCV induced end stage liver disease:**  
poor therapy efficacy  
liver transplantation  
universal infection of liver graf


**Neutralizing antibodies ?**

# In vitro characterization of anti-HCV mAb-2A5






## HCVpp



## HCVcc



# In vivo characterization of anti-HCV mAb-2A5



## Conclusion:

mAb-2A5 neutralizes HCV *in vitro* and *in vivo*.

mAb-2A5 could be used to prevent HCV infection of liver graft.

# Acknowledgements

## Ghent University

Isabelle Desombere

Lieven Verhoye

Freya Van Houtte

Ali Farhodi

Karin Weening

Koen Vercauteren

Geert Leroux-Roels

Philip Meuleman

## Karolinska University

Daniel Johansson

Mats Persson

## Stanford University

Zhen-Yong Keck

Steven Foung

## University of Nottingham

Richard Urbanowicz

Jonathan Ball

**Reagents:** Charles M. Rice  
Jens Bukh  
Thomas F. Baumert  
Arvind Patel  
Jane A. McKeating

**Funding:**

